http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 19 Sep 2025 21:45:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Shares+for+Debt+Settlement/25356664.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 19, 2025 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "<strong>Creditor</strong>") related to an aggregate of $225,010 in debt (the "<strong>Debt</strong>") owing for services provided by the Creditor to the Company. In full satisfaction and settlement of the Debt, the Company issued an aggregate of 112,505 common shares in the capital of the Company (the "<strong>Debt Shares</strong>") at http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Shares+for+Debt+Settlement/25356664.html Fri, 19 Sep 2025 21:45:00 -0500 XPHYF http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Shares+for+Debt+Settlement/25356664.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 19, 2025 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "<strong>Creditor</strong>") related to an aggregate of $225,010 in debt (the "<strong>Debt</strong>") owing for services provided by the Creditor to the Company. In full satisfaction and settlement of the Debt, the Company issued an aggregate of 112,505 common shares in the capital of the Company (the "<strong>Debt Shares</strong>") at http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Shares+for+Debt+Settlement/25356664.html Fri, 19 Sep 2025 21:45:00 -0500 XPHYF http://www.streetinsider.com/Press+Releases/BioNxt+Advances+Semaglutide+Oral+Dissolvable+Film+%28ODF%29+Program+with+Successful+Proof-of-Concept+and+Prototype+Development/25331299.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2025 / </strong>BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary.</p><p>Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these in-house platforms achieved highly promising results, generating first prototypes of Semaglutide-ODF formulations with strong performance characteristics. The prototypes demonstrated rapid disintegration, homogeneous film quality, good processability during http://www.streetinsider.com/Press+Releases/BioNxt+Advances+Semaglutide+Oral+Dissolvable+Film+%28ODF%29+Program+with+Successful+Proof-of-Concept+and+Prototype+Development/25331299.html Mon, 15 Sep 2025 03:05:00 -0500 XPHYF http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Advances+Semaglutide+Oral+Dissolvable+Film+%28ODF%29+Program+with+Successful+Proof-of-Concept+and+Prototype+Development/25331299.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2025 / </strong>BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary.</p><p>Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these in-house platforms achieved highly promising results, generating first prototypes of Semaglutide-ODF formulations with strong performance characteristics. The prototypes demonstrated rapid disintegration, homogeneous film quality, good processability during http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Advances+Semaglutide+Oral+Dissolvable+Film+%28ODF%29+Program+with+Successful+Proof-of-Concept+and+Prototype+Development/25331299.html Mon, 15 Sep 2025 03:05:00 -0500 XPHYF http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23375404.html <p><i><strong>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a "<strong>Common Share</strong>") at a price of $0.27 per Common Share for gross proceeds of $270,000 http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23375404.html Wed, 19 Jun 2024 19:00:00 -0500 XPHYF http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23375404.html <p><i><strong>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a "<strong>Common Share</strong>") at a price of $0.27 per Common Share for gross proceeds of $270,000 http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23375404.html Wed, 19 Jun 2024 19:00:00 -0500 XPHYF http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23376940.html <p><i><strong>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a "<strong>Common Share</strong>") at a price of $0.27 per Common Share for gross proceeds of $270,000 http://www.streetinsider.com/Press+Releases/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23376940.html Wed, 19 Jun 2024 19:00:00 -0500 XPHYF http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23376940.html <p><i><strong>NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / </strong>BioNxt Solutions Inc. ("<strong>BioNxt</strong>" or the "<strong>Company</strong>") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a "<strong>Common Share</strong>") at a price of $0.27 per Common Share for gross proceeds of $270,000 http://www.streetinsider.com/ACCESS+Newswire/BioNxt+Solutions+Announces+Closing+of+Second+Tranche+of+Non-Brokered+Private+Placement/23376940.html Wed, 19 Jun 2024 19:00:00 -0500 XPHYF